Introduction
Numerous studies have shown that a tumor establishes its own vasculature in order to reach macroscopic size (1) . Consequently, the up-regulation of angiogenic factors is often an important step in the development of aggressive metaplasia. Vascular endothelial growth factor-A (VEGF-A) 1 is a potent angiogenic agent that is often up-regulated during cancer development (2) . VEGF-A deregulation appears to play a particularly important role in the development of glioblastoma, a fast growing and highly vascularized brain cancer with poor prognosis. Up-regulation of VEGF-A is a common event in glioblastomas (3) , and VEGF-A expression is correlated with tumor grade and vascularity in gliomas (4) . Numerous studies in animal models have shown that the inhibition of VEGF-A using neutralizing antibodies (5), dominant negative VEGF receptor mutants (6, 7) and antisense constructs (8, 9 ) causes regression of blood vessels, inhibits growth of glioma cells in vivo and suppresses tumorigenicity of glioblastoma cells in immunodeficient mice (8) (9) (10) (11) . Taken together, these findings indicate that strategies to down-regulate VEGF-A can potentially be applied to treat highly vascularized glioblastomas.
VEGF-A expression is regulated by a wide variety of reagents, signaling pathways and external stimuli, including hypoxia, hormones, cytokines and oncogenes. The VEGF-A promoter contains a hypoxia response element (HRE) consisting of a hypoxia inducible factor-1 binding site and a hypoxia inducible factor-1 ancillary sequence (HAS) that mediates VEGF-A activation by hypoxia and nitric oxide (12) (13) (14) (15) . Two hypoxia inducible factors (Hifs) , and endothelial PAS domain protein 1 (EPAS1, also called Hif-2α), have been shown to mediate 3 by guest on July 16, 2017 http://www.jbc.org/ Downloaded from VEGF-A activation through binding to the HRE upon dimerization with the aryl hydrocarbon receptor nuclear translocator gene product (ARNT, also called Hif-1β). The transforming growth factor-β pathway and AP-1 protein have been shown to synergize or potentiate hypoxia induced VEGF-A transcriptional activation (16, 17) . AP-1 has also been implicated in the induction of VEGF-A by lead in human astrocytes and ionizing radiation in human glioblastoma cells independent of the hypoxia pathway (18, 19) . 17β-estradiol induces VEGF-A transcription through a variant estrogen response element on the VEGF-A promoter (20) . Interleukin-1, epidermal growth factor, protein kinase C, Ras, mitogen-activated protein kinase and phosphatidylinosital 3-kinase pathways have all been implicated in stimulating VEGF-A expression in various cell systems (18, 19, (21) (22) (23) . In addition to Hifs and AP-1, SP1 and AP-2 have also been shown to regulate VEGF-A transcription under various conditions (24) .
Many glioblastoma cells constitutively express high levels of VEGF-A without any external stimuli, suggesting that they express intrinsic factors that activate VEGF-A expression to high levels independent of environmental signals. For example, U87MG human glioblastoma cells have been found to express much higher levels of VEGF-A than NIH3T3 fibroblasts, human fetal astrocytes and A172 glioma cells under tissue culture conditions (25, 26) . Given the prominent role of VEGF-A in tumor angiogenesis, it is critical to understand the molecular basis of high level VEGF-A expression in tumor cells. In this study, we investigated the cis-acting elements and transcription factors involved in constitutive VEGF-A up-regulation in U87MG cells. We identified a new regulatory region of VEGF-A that is selectively accessible to DNase I digestion in tumorigenic glioblastoma cell lines and functions as a potent enhancer in U87MG-based reporter assays. This new regulatory region, which we will refer to as 'HS-1100', spans 4 by guest on July 16, 2017 http://www.jbc.org/ Downloaded from approximately four-hundred base pairs (bps) of the VEGF-A gene centered on bp -1100 relative to the transcription initiation site, and is highly conserved among human, mouse and rat.
We demonstrate that the HRE, which is located within HS-1100, plays an important role in upregulating VEGF-A expression in U87MG glioblastoma cells, and that this is correlated with an enhanced binding of EPAS1 to the HRE. We further show that this enhanced binding appears to be due not to enhanced expression of EPAS1, but rather to the presence of a chromatin architecture that is more permissive for EPAS1 binding in U87MG cells than in other cell types.
These results suggest that constitutive chromatin accessibility may facilitate the binding of EPAS1 to the HRE within HS-1100, which acts to up-regulate VEGF-A expression in U87MG cells.
Experimental Procedures
Cell Culture-The human cervical carcinoma HeLa, the human embryonic kidney HEK293, the human glioblastoma U87MG, U118MG and A172 cell lines were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. The human erythroleukemia HEL and chronic myelogenous leukemia K562 cell lines were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum. The human glioblastoma T98G cell line was cultured in Eagle's minimum essential medium with Earl's BSS supplemented with 10% fetal bovine serum. All cell lines were maintained in a 5% CO 2 atmosphere at 37°C. Quantitative RT-PCR Analysis of VEGF-A mRNA Level-Total RNA was prepared using the High Pure RNA Isolation Kit (Roche) and subjected to a real-time quantitative RT-PCR analysis using the Taqman assay as described previously (27) . Each sample was analyzed in triplicates. The VEGF-A mRNA levels were normalized by the 18S ribosomal RNA levels. Western Blotting of Nuclear Extracts-1x10 7 U87MG or HEK293 cells were pelleted, resuspended in 400 µl of buffer A (10mM Tris pH8.0, 1.5mM MgCl 2 , 10mM KCl, 1mM dithiothreitol and 1mM phenylmethylsulfonyl fluoride) and incubated on ice for 10 min. Cells were lysed by adding 25 µl of 10% IGEPAL and vortexing vigorously for 10 seconds. After centrifugation at 13,000g for 30 seconds at 4°C, the pellets were resuspended in 100 µl of icecold buffer C (20mM Tris pH8.0, 420mM NaCl, 1.5mM MgCl 2, 0.2mM EDTA, 25% glycerol, 1mM dithiothreitol and 1mM phenylmethylsulfonyl fluoride) and gently shaken at 4°C for 30 min. After centrifugation at 4°C for 15 min, the supernatants were saved and protein concentrations were determined using the Bradford assay (Bio-Rad). 50µg protein from each nuclear extract was analyzed via electrophoresis on a 4-20% Tris-HCl gel (Bio-Rad) followed by western blotting using anti-EPAS1 and anti-ARNT antibodies (Novus Biologicals). The Western blots were visualized by SuperSignal West Dura Extended Duration Substrate (Pierce).
Plasmids-The

ELISA Measurement of Secreted VEGF-A-
Chromatin Immunoprecipitation Assay-Chromatin immunoprecipitation (ChIP) assays were carried out using the Acetyl-Histone H3 Immunoprecipitation (ChIP) Assay Kit (Upstate Biotechnology) according to the manufacturer's instructions. The antisera used are as follows:
1.5-2.0 µg/ml rabbit control serum (Santa Cruz), 1.5 µg/ml anti-EPAS1 antiserum (Novus Biologicals), and 2.0 µg/ml anti-E2F1 antiserum (Santa Cruz). After ChIP, the precipitated genomic DNA was analyzed by Taqman using the following primers and probes. Sequence Alignment-Sequence alignments were performed using the Align X module of the Vector NTI Suite 6 software package with default settings. The sequences used are from GenBank # AF095785 (human VEGF-A), # U41383 (mouse VEGF-A), # U22373 (rat VEGF-A) and unpublished data (B. Chen and E.J. Rebar).
Results
Identification of a Cell-Type Specific DNase I Accessible Region in the VEGF-A
Promoter-VEGF-A expression levels in various human cell lines were measured by quantitative RT-PCR (Taqman) and ELISA assays (Table I) . A human glioblastoma cell line, U87MG, exhibited 9 to 50 fold higher VEGF-A mRNA levels than several other cell lines, including HeLa, HEK 293, HEL and K562. Correspondingly, U87MG cells also secreted much higher amounts of VEGF-A protein into culture supernatants. The high endogenous VEGF-A levels in U87MG cells are consistent with the fact that these cells are derived from a highly vascularized tumor type.
To delineate the mechanisms of VEGF-A up-regulation, we set out to identify regulatory elements and transcription factors that activate VEGF-A transcription in U87MG cells. Since DNase I accessible regions often harbor cell-type specific enhancer elements, DNase I hypersensitive site mapping was performed in the above mentioned cell lines (Figure 1 ). Two hypersensitive sites centered at bp -550 and +1 relative to the transcription start site of the VEGF-A promoter were clearly observed in all cell lines. A third and weaker hypersensitive site centered at bp +500 could also been seen in all cell lines, which was more apparent under longer exposure (data not shown). These three hypersensitive sites have previously been described in a variety of cell types (27) . A fourth and very intense hypersensitive site centered at bp -1100 of the VEGF-A promoter, which we will refer to as 'HS-1100', was only observed in U87MG cells. These data suggest that the -550, +1 and +500 DNase I hypersensitive regions may contain elements that are important for the normal regulation of VEGF-A in various cell types, while HS-1100 may contain cell-type specific regulatory elements that contribute to the extremely high level of VEGF-A expression in U87MG cells. An alignment of promoter regions of VEGF-A (Figure 2A Since HS-1100 harbors the HRE, we tested whether the HRE contributes to the function of HS-1100. A 3-bp substitution in the Hif-1 binding site that has previously been shown to abolish the hypoxia response (14) caused ~ 70% reduction of HS-1100 enhancer activity in U87MG cells (Figure 3B ), suggesting that the HRE accounts for a significant part of the enhancer activity of HS-1100 in these cells. Immunoblotting with nuclear extracts showed that EPAS1 and ARNT were expressed at comparable levels in U87MG and HEK293 cells ( Figure   4 ), whereas Hif-1α was hardly detectable in both cell lines (data not shown). This result indicates that the different VEGF-A levels observed in U87MG and HEK293 cells cannot be explained by differential expression levels of Hifs. Next, we tested whether there is a difference in the binding of EPAS1 to the HRE in these two cell lines. Although EPAS1 can bind to the HRE in in vitro gel mobility shift assays (28), the binding of EPAS1 to the endogenous chromosomal locus in vivo has not to our knowledge been demonstrated. To determine this, chromatin immunoprecipitation (ChIP) assays were performed in U87MG and HEK293 cells. In U87MG cells (Figure 5A ), immunoprecipitation with an anti-EPAS1 antiserum enriched a DNA region containing the HRE by 5.7-fold compared with a preimmune serum. As an internal control for specificity, a site centered at 1050-bp downstream of the VEGF-A transcription start site was not significantly enriched. In contrast, immunoprecipitation with the anti-EPAS1 antiserum did not significantly enrich the HRE site in HEK293 cells ( Figure 5B ). As a positive control in HEK293 cells, an anti-E2F1 antiserum could enrich an E2F1 binding site within a DNase I accessible region on p14 ARF promoter 2 by 3.7-fold. These results show that EPAS1 can bind efficiently to the HRE in U87MG cells, whereas it cannot do so in HEK293 cells, most likely due to the less accessible nature of the HRE in this cell type.
Inhibition of Endogenous VEGF-A Levels by a Dominant-Negative Mutant of EPAS1 in
U87MG Cells-To confirm that the HRE contributes to the high endogenous levels of VEGF-A in U87MG cells, a dominant-negative mutant of EPAS1 lacking the C-terminal activation domain, EPAS1(1-481), was constructed. This mutant EPAS1 retains the ability to heterodimerize with ARNT and to bind to the HRE, but it cannot transactivate the VEGF-A promoter (29) . Previous studies have shown this mutant EPAS1 inhibits desferrioxamine induction of endogenous VEGF-A mRNA levels in human umbilical vein endothelial cells (29) .
When EPAS1(1-481) was co-transfected into U87MG cells, it was able to repress the enhancer activity of HS-1100 in a dose-dependent and HRE-dependent manner ( Figure 6 ). EPAS1(1-481) was subsequently cloned into an adenoviral vector that was then used to infect U87MG cells. The EPAS1(1-481) adenovirus infected U87MG cells, which expressed a high level of the 53kD truncated EPAS1 protein ( Figure 7A ), showed ~ 50% reduction of the endogenous VEGF-A mRNA and protein levels compared with U87MG cells infected with a β-galactosidase control virus ( Figure 7B ). These data suggest that binding of the HRE by EPAS1 (or other Hifs) contributes to constitutive activation of VEGF-A in U87MG cells.
Correlation of Tumorigenicity, VEGF-A Expression and the Accessibility of HS-1100 in
Glioblastoma Cell Lines-To determine whether the chromatin accessibility of HS-1100 is a general feature of glioblastomas, several additional glioblastoma cell lines with various degrees of tumorigenicity were tested for both their endogenous VEGF-A levels (Table II) but it is conceivable that Hif1α would act similarly as EPAS1. The relative levels of endogenous EPAS1 and Hif1α in U87MG cells are unknown. We have observed that overexpression of EPAS1 is more potent than overexpression of Hif1α in activating reporter genes that contain the HRE in U87MG cells (data not shown), which is consistent with results from other studies (34, 35) . In addition, EPAS1 but not Hif1α is enriched in highly vascularized tissues, and significant up-regulation of VEGF-A is highly correlated with elevated expression of EPAS1 but not Hif1α in renal cell carcinomas and hemangioblastomas (35, 36) . These results suggest that EPAS1, rather than Hif1α, is the major player in activating VEGF-A transcription through the HRE in U87MG cells.
The identification of a cell-type specific enhancer whose chromosomal accessibility is correlated with high levels of VEGF-A expression in tumorigenic glioblastoma cell lines could have implications for the development of anti-angiogenic cancer therapies. Sequences within the accessible HS-1100 could serve as targets for transcription factor based therapeutics, such as engineered zinc finger DNA binding proteins (27) . Activation of the HRE-mediated pathway has been demonstrated in many cancers and has been targeted for the development of cancer therapeutics (37) . Our present study demonstrates that the HRE is also required for the high level of VEGF-A expression in tumorigenic glioblastoma cell lines. Blockade of the HRE-mediated pathway by a polypeptide that disrupts the interaction between Hif1α and p300/CBP has been suggested as a new approach to cancer therapy (38) . The potential drawback of this approach is that it is likely to interfere with other transcriptional systems requiring p300/CBP as well as the hypoxia pathway in normal tissues. In contrast, inhibition of the HRE-mediated pathway by DNA binding proteins that competitively bind to the HRE but lack any activation function would be selectively effective in tumor cells that have an accessible chromosomal HS-1100. Molecules that regulate the remodeling of chromatin structures at HS-1100 could also be interesting therapeutic agents with a selectivity for highly malignant glioblastomas. In summary, our studies on understanding how multiple elements and factors coordinate to regulate VEGF-A transcription could provide useful therapeutic strategies for treating cancer. 
